Claritas Pharmaceuticals

Claritas Pharmaceuticals is at the forefront of developing the next generation of cannabinoid therapies. Claritas Pharmaceuticals' product R-107 is a nitric oxide-releasing compound used to treat non-COVID and COVID-related pulmonary diseases. Claritas focuses on areas of unmet medical needs and leverages its expertise to find solutions that improve health outcomes and significantly enhance people's lives.